1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Acadia Pharmaceuticals said its Head of Research and Development, Elizabeth H.Z. Thompson, Ph.D., plans to retire for personal reasons. She will stay in the role until a successor is appointed and then serve as a consultant through at least the end of 2026, including through the planned Phase 2 readout of remlifanserin in Alzheimer's disease psychosis. The filing matters to shareholders because it changes leadership of the company's research program during a key clinical period.
Dr. Thompson informed the company of her planned retirement on April 27, 2026, and the company announced it on April 30, 2026.
She will remain Head of Research and Development until a successor is appointed, then serve as a consultant through at least the end of 2026.
The company has initiated a search for a replacement; no successor is named in the filing.
The Phase 2 remlifanserin study in Alzheimer's disease psychosis continues to recruit and remains blinded, and the company does not yet know outcomes.
PayPal announced on April 29, 2026 a strategic reorganization into three business units, along with leadership changes. EVPs Michelle Gill and Diego Scotti will leave the company, with Gill's departure effective June 2, 2026. The company said it will provide more details on the new operating model during its May 5 earnings call.
Effective June 2, 2026, Michelle Gill ceases to serve as EVP, General Manager, Small Business and Financial Services, and Diego Scotti ceases to serve as EVP, General Manager, Consumer Group.
Gill's separation and release agreement is dated April 27, 2026, and makes her eligible for severance under the Executive Change in Control and Severance Plan for a termination without cause.
The reorganization moves PayPal to a three-business model: Checkout Solutions & PayPal, Consumer Financial Services & Venmo, and Payment Services & Crypto.
Frank Keller was named President, Checkout Solutions & PayPal, and Alexis Sowa and Jeff Pomeroy were named interim leads of two of the new units.
Fluor's subsidiary FDEE Consulting entered a consulting agreement on April 26, 2026 with Mark E. Fields, the company's former Group President, Strategic Projects. He will provide advisory services for up to six months starting April 27, 2026, at $670 per hour. The filing shows a limited, short-term arrangement with no financial figures beyond the hourly rate.
Consulting agreement dated April 26, 2026, between FDEE Consulting, Inc. and Mark E. Fields
Services at $670 per hour for up to six months, beginning April 27, 2026
Full agreement to be filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2026
Teleflex said Jason Weidman, previously a senior leader at Medtronic, will become President and Chief Executive Officer on June 8, 2026, succeeding interim CEO Stuart Randle, who will remain on the Board. Weidman is also expected to join the Board as a director at that time. The filing's compensation terms include a $1 million base salary and a $7 million sign-on restricted stock grant, which shareholders may track in future proxy and SEC filings.
Start date is June 8, 2026; Weidman is expected to join the Board as a director on that date.
Offer letter dated April 26, 2026 provides a $1 million base salary and a target annual bonus of 125% of base salary.
Sign-on restricted stock grant has a grant date fair value of $7 million; stock options have a grant date fair value of $1 million.
Chairman Stephen Klasko said the appointment follows the divestitures and the planned $1 billion share buyback and $800 million debt paydown.
At its April 29, 2026 annual meeting, Carlisle Companies stockholders elected Sheryl D. Palmer and Jesse G. Singh as directors, approved on an advisory basis the 2025 executive pay, and ratified Deloitte & Touche LLP as auditor for 2026. Director Jonathan R. Collins resigned, effective after the meeting, after a change in his employment, and the company said the departure was not due to any disagreement with the company. Executive Vice President Scott C. Selbach also retired on April 28, 2026.
Sheryl D. Palmer received 31,348,097 votes for and 3,257,426 against, and Jesse G. Singh received 32,292,836 for and 2,306,055 against.
Advisory vote on 2025 executive compensation: 30,209,063 for and 4,331,231 against.
Deloitte & Touche LLP ratified as independent auditor for 2026 with 37,101,448 votes for and 132,073 against.
Board fixed the number of directors at seven following Collins' resignation; Selbach retired April 28, 2026 after more than 35 years.
Match Group's board appointed Raina Moskowitz as a director, effective at the 2026 annual meeting, filling the vacancy left by Pamela S. Seymon's previously announced resignation. The filing says the board has not yet decided which committees she will join, and it discloses no related party transactions.
Raina Moskowitz appointed to the board on April 29, 2026, effective at the 2026 annual meeting
Term expires at the 2027 annual meeting of stockholders
Fills vacancy from Pamela S. Seymon's resignation, also effective at the 2026 annual meeting
Manuel Bronstein to stand for election to the board at the 2026 annual meeting, as announced February 17, 2026
ResMed said CFO Brett Sandercock will retire, with Aaron Bloomer, formerly CFO of Exact Sciences, taking over as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer effective May 4, 2026. The company said the retirement was not the result of any disagreement on operations, policies or practices, and it reiterated its fiscal 2026 outlook alongside the announcement.
Sandercock serves as CFO until May 4, 2026, then as Special Advisor to Chairman and CEO Mick Farrell through December 31, 2026, and in a consulting role through December 31, 2027.
Bloomer, age 40, receives a $725,000 base salary, a $150,000 sign-on bonus and a $3,300,000 long-term performance equity grant when he joins.
Bloomer is also eligible for a $3,300,000 equity grant in November 2026 for fiscal year 2027.
ResMed reiterated fiscal 2026 outlook, including gross margin of 62-63%.
Cognex's board determined on April 29, 2026 that Joerg Kuechen will no longer be deemed an executive officer under SEC rules, though he continues as Head of Mergers and Acquisitions. The same day, shareholders approved every proposal at the 2026 Annual Meeting, including director elections, an amendment to the 2023 Stock Option and Incentive Plan, and the ratification of KPMG LLP as auditor for fiscal 2026.
Kuechen's status change applies to the SEC's executive officer and Section 16 officer definitions; he remains with the company as Head of Mergers and Acquisitions.
Of 167,013,856 shares outstanding and entitled to vote, 153,890,280 were represented at the April 29, 2026 meeting.
Matthew Moschner, Angelos Papadimitriou and Christopher Donato were elected as directors for terms ending in 2029.
Say-on-pay received 109,615,176 for votes and 29,685,048 against; KPMG ratification received 153,641,083 for votes and 83,521 against.
Marcus Theatres Chief Financial Officer Jeffry F. Tomachek will be promoted to president of Marcus Theatres effective May 1, 2026, succeeding Mark A. Gramz, who retires that day after 55 years with the company. Gramz's retirement date was moved from March 31, 2026, as announced on April 7, 2026, and he will then advise the company as an independent contractor.
Mark A. Gramz's retirement date changed from March 31, 2026 to May 1, 2026, per the April 7, 2026 announcement.
Jeffry F. Tomachek, currently CFO of Marcus Theatres, will become president of Marcus Theatres effective May 1, 2026.
Tomachek began at Marcus Theatres in 1998 and was named executive vice president and chief financial officer in 2020.
After retirement, Gramz will continue as an advisor to the company in an independent contractor capacity.
Halozyme appointed Darren Snellgrove, currently Vice President, Investor Relations at Johnson & Johnson, as Chief Financial Officer effective June 8, 2026. Interim CFO David Ramsay will move to an advisory role during a brief transition period. The filing discloses a $670,000 base salary, a bonus target of 50% of salary, and new-hire equity awards with a total grant date value of $7.2 million.
Start date is June 8, 2026; he will report to President and CEO Helen Torley.
Base salary of $670,000 and a bonus target of 50% of base salary, prorated in 2026.
New-hire equity totals $7.2 million: $3.2 million in RSUs and $4.0 million in stock options, plus a $350,000 sign-on cash bonus.
Previously CFO of Johnson & Johnson's Pharmaceutical sector from August 2021 to May 2025.
Moving iMage Technologies said CFO William F. Greene retired and resigned effective April 27, 2026, and that the resignation was not due to any disagreement with the company. The board named Bart Bedard as Chief Financial Officer effective the same day, with a $200,000 base salary, a $10,000 signing bonus and 75,000 stock options.
William F. Greene resigned as CFO effective April 27, 2026 and will advise the company through approximately October 2026
Bart Bedard named CFO effective April 27, 2026; base salary $200,000 per year
Bedard's offer includes a $10,000 signing bonus and 75,000 stock options, with 25% vesting immediately and 75% over three years
Offer letter provides full vesting of unvested options upon a change of control
Entegris said on April 30, 2026 that Sukhi Nagesh will become Senior Vice President and Chief Financial Officer effective May 18, 2026, succeeding Michael Sauer, who has served as interim CFO since March 1, 2026. Sauer will continue as Vice President, Chief Accounting Officer, and the filing says his departure from the interim role was not the result of any disagreement with the company. For shareholders, this sets a permanent finance chief and discloses his pay terms, but the filing contains no financial results.
Base salary of $590,000 per year, with an annual target bonus of 70% of base salary, prorated for 2026
Sign-on bonus of $200,000, repayable if he resigns voluntarily within 12 months of hire
Initial equity grant with a target grant date value of $2,100,000, split 50% time-based restricted share units and 50% performance share units
Severance if terminated without cause outside a change in control: lump sum equal to annual base salary plus 12 months of subsidized medical coverage
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.